### Wednesday, June 17, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 12:00</td>
<td>POSTER SESSION SET UP</td>
</tr>
<tr>
<td>08:30 – 09:15</td>
<td>Article number “MEET THE PROFESSOR” SESSIONS</td>
</tr>
<tr>
<td>Room A</td>
<td>IV. MASSES IN THE MEDIASTINUM: PRIMARY MEDIASTINAL LYMPHOMA AND</td>
</tr>
<tr>
<td></td>
<td>INTERMEDIATE TYPES</td>
</tr>
<tr>
<td></td>
<td>P.M.W. Johnson, Southampton (UK)</td>
</tr>
<tr>
<td></td>
<td>repeated on Thursday, June 18, in Auditorium, University Campus</td>
</tr>
<tr>
<td>Room B</td>
<td>VII. ARE LYMPHOMAS DRIVEN BY EPIGENETIC LESIONS?</td>
</tr>
<tr>
<td></td>
<td>A.M. Melnick, New York, NY (USA)</td>
</tr>
<tr>
<td></td>
<td>repeated at 09:30 in Cinema Corso</td>
</tr>
<tr>
<td>Cinema Corso</td>
<td>X. CHALLENGES AND FUTURE DIRECTIONS IN PERIPHERAL T-CELL LYMPHOMA</td>
</tr>
<tr>
<td></td>
<td>K.J. Savage, Vancouver, BC (Canada)</td>
</tr>
<tr>
<td></td>
<td>repeated at 09:30 in Room B</td>
</tr>
<tr>
<td>Auditorium, University Campus</td>
<td>III. CURRENT CONCEPTS IN PRIMARY CENTRAL NERVOUS LYMPHOMA</td>
</tr>
<tr>
<td>Aula Magna, University Campus</td>
<td>IX. IS IT ONLY ABOUT MYC? HOW TO APPROACH THE DIAGNOSIS OF DIFFUSE</td>
</tr>
<tr>
<td></td>
<td>L. Quintanilla-Martinez, Tuebingen (Germany)</td>
</tr>
<tr>
<td></td>
<td>repeated on Friday, June 19, in Cinema Corso</td>
</tr>
<tr>
<td>09:30 – 10:15</td>
<td>5 parallel sessions</td>
</tr>
<tr>
<td>Room A</td>
<td>VIII. TREATMENT OF CLL, WHERE ARE WE HEADING?</td>
</tr>
<tr>
<td></td>
<td>S.M. O’Brien, Irvine, CA (USA)</td>
</tr>
<tr>
<td></td>
<td>repeated on Friday, June 19, in Auditorium, University Campus</td>
</tr>
<tr>
<td>Room B</td>
<td>X. CHALLENGES AND FUTURE DIRECTIONS IN PERIPHERAL T-CELL LYMPHOMA</td>
</tr>
<tr>
<td></td>
<td>K.J. Savage, Vancouver, BC (Canada)</td>
</tr>
<tr>
<td>Cinema Corso</td>
<td>VII. ARE LYMPHOMAS DRIVEN BY EPIGENETIC LESIONS?</td>
</tr>
<tr>
<td></td>
<td>A.M. Melnick, New York, NY (USA)</td>
</tr>
<tr>
<td>Auditorium, University Campus</td>
<td>XII. THERAPEUTIC EXPLOITATION OF AUTOLOGOUS T-CELL ACTIVATION IN B-CELL</td>
</tr>
<tr>
<td></td>
<td>A. Younes, New York, NY (USA)</td>
</tr>
<tr>
<td></td>
<td>repeated on Thursday, June 18, in Room A</td>
</tr>
</tbody>
</table>
VI. FDG-PET AS A BIOMARKER IN LYMPHOMA: FROM QUALITATIVE TO QUANTITATIVE ANALYSIS
M. Meignan, Creteil (France)
repeated on Friday, June 19, in Aula Magna, University Campus

10:15 – 10:35
COFFEE BREAK
Marquee

10:35 – 12:00
EDUCATIONAL SYMPOSIA
2 parallel sessions
Room A – Marquee
HISTOLOGICAL TRANSFORMATION IN LYMPHOMA: CLINICAL, PATHOLOGICAL AND MOLECULAR FEATURES
Chair: J.G. Gribben, London (UK)

LECTURES:
XIII. MOLECULAR PATHOGENESIS OF TRANSFORMED LYMPHOMAS
D. Rossi, Novara (Italy)
XIV. THE PATHOLOGY OF TRANSFORMATION OF LYMPHOMA
R. Gascoyne, Vancouver, BC (Canada)
XV. CLINICAL ASPECTS OF TRANSFORMED LYMPHOMA
J.G. Gribben, London (UK)

Room B
HODGKIN LYMPHOMA – CHALLENGES AND OPPORTUNITIES
Chair: R.H. Advani, Stanford, CA (USA)

LECTURES:
XVI. EARLY STAGE HODGKIN LYMPHOMA
J.A. Radford, Manchester (UK)
XVII. TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA
A. Engert, Cologne (Germany)
XVIII. MANAGEMENT OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA
R.H. Advani, Stanford, CA (USA)

12:00 – 18:30
POSTER SESSION
Marquee
Abstract number
(printing of the posters sponsored by Takeda Oncology)
148 - 170 PATHOLOGY AND BIOLOGY
171 - 181 HODGKIN LYMPHOMA
182 - 186 CLL
187 - 201 INDOLENT LYMPHOMA
202 - 209 MANTLE CELL LYMPHOMA
210 - 224 AGGRESSIVE B-CELL LYMPHOMA
225 - 230 EXTRANODAL LYMPHOMA
231 - 250 T-CELL LYMPHOMA
251 - 259 IMAGING
260 - 279 PRE-CLINICAL STUDIES
280 - 287 EARLY CLINICAL TRIALS
OT07 – ONGOING TRIALS
OT15

12:00 – 13:00
LUNCH TIME AND POSTER VIEWING
Marquee

13:00 – 14:00
OPENING OF THE CONFERENCE
Room A, B and Marquee
WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona (Switzerland)
HENRY KAPLAN MEMORIAL LECTURE AND SAN SALVATORE FOUNDATION AWARD

001 THERAPY OF LYMPHOMA INSPIRED BY FUNCTIONAL AND STRUCTURAL GENOMICS
L.M. Staudt, Bethesda, MD (USA)

14:00 – 15:15
PLENARY SESSION
Room A, B and Marquee (overflow area)

Co-Chairs: G.P. Canellos, Boston, MA (USA) and J.W. Friedberg, Rochester, NY (USA)

14:00 008 RESPONSE-ADAPTED THERAPY BASED ON INTERIM FDG-PET SCANS IN ADVANCED HODGKIN LYMPHOMA: FIRST ANALYSIS OF THE SAFETY OF DESCALATION AND EFFICACY OF ESCALATION IN THE INTERNATIONAL RATHL STUDY (CRUK/07/033)
P.M.W. Johnson, Southampton (UK)

14:15 Discussant: A. Engert, Cologne (Germany)

14:25 009 ADDITION OF THIOTEPA AND RITUXIMAB TO ANTIMETABOLITES SIGNIFICANTLY IMPROVES OUTCOME IN PRIMARY CNS LYMPHOMA: FIRST RANDOMIZATION OF THE IELSG32 TRIAL
A.J. Ferreri, Milan (Italy)

14:40 Discussant: T.T. Batchelor, Boston, MA (USA)

14:50 010 NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES AND CLASSICAL HODGKIN LYMPHOMA: UPDATED RESULTS OF A PHASE 1 STUDY (CA209-039)
J. Timmerman, Los Angeles, CA (USA)

15:05 Discussant: A. Younes, New York, NY (USA)

15:15 – 15:40 Marquee

COFFEE BREAK

15:40 – 16:40
AACR-ICML JOINT SESSION: SPECIAL LECTURES
Room A, B and Marquee (overflow area)

Co-Chairs: F. Cavalli, Bellinzona (Switzerland) and M. Foti, Philadelphia, PA (USA)

15:40 004 UPDATE ON THE REVISION OF THE WHO LYMPHOMA CLASSIFICATION
S.H. Swerdlow, Pittsburgh, PA (USA)

16:10 005 WHAT’S NEW IN MULTIPLE MYELOMA?
S.V. Rajkumar, Rochester, MN (USA)

16:55 – 17:15 BREAK

17:15 – 18:15 “FOCUS ON…” SESSIONS
6 parallel sessions
Room A

IMIDs IN LYMPHOMA
Chair: N. Fowler, Houston, TX (USA)

17:15 011 INDEPENDENT REVIEW OF CT RESPONSES IN THE TRIAL SAKK35/10 COMPARING RITUXIMAB WITH OR WITHOUT LENALIDOMIDE IN UNTREATED FL PATIENTS IN NEED OF THERAPY
E. Zucca, Bellinzona (Switzerland)
17:25  012  RITUXIMAB+LENALIDOMIDE IN MALT LYMPHOMA: FINAL RESULTS  
M. Raderer, Vienna (Austria)

17:35  013  LENALIDOMIDE ADDED TO BENDAMUSTINE-RITUXIMAB FOR UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PHASE 1 STUDY  
J.S. Abramson, Boston, MA (USA)

17:45  014  RITUXIMAB, LENALIDOMIDE, BENDAMUSTINE SECOND LINE THERAPY IN MANTLE CELL LYMPHOMA: A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)  
F. Zaja, Udine (Italy)

17:55  015  RITUXIMAB, BENDAMUSTINE AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA NOT ELIGIBLE FOR SALVAGE CHEMOTHERAPY. PHASE II TRIAL - SAKK 38/08  
F. Hitz, St. Gallen (Switzerland)

18:05  016  A PHASE III TRIAL OF THE COMBINATION OF ROMIDEPSIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA AND MYELOMA  
N. Mehta-Shah, New York, NY (USA)

Room B

GENOMIC ALTERATIONS  
Chair: G. Gaidano, Novara (Italy)

17:15  017  SEQUENCE-BASED PANOMICS ANALYSES BY THE ICGC MMML-SEQ DECIPHERS MULTI-LAYER PATHWAY DEREGLATION IN GERMINAL CENTER DERIVED B-CELL LYMPHOMAS  
R. Siebert, Kiel (Germany)

17:25  018  STRUCTURAL VARIANTS IN GERMINAL-CENTER DERIVED B-CELL LYMPHOMAS: ANALYSES IN THE FRAMEWORK OF THE ICGC MMML-SEQ PROJECT  
C. Lopez, Kiel (Germany)

17:35  019  COMPREHENSIVE GENOMIC PROFILING OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE CLINICAL SETTING  
J. He, Cambridge, MA (USA)

17:45  020  TARGETED GENOMIC SEQUENCING PROSPECTIVELY IDENTIFIES CLINICALLY RELEVANT GENETIC ALTERATIONS ACROSS LYMPHOMA SUBTYPES  
C.L. Batlevi, New York, NY (USA)

17:55  021  POSTTRANSPLANT DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA: NEW GENETIC FINDINGS  
I. Wlodarska, Leuven (Belgium)

18:05  022  MICRORNA-150 INFLUENCES MICROENVIRONMENTAL INTERACTIONS AND PROGNOSIS OF FOLLICULAR LYMPHOMA  
K. Musilova, Brno (Czech Republic)

Room C

CLINICOPATHOLOGICAL CORRELATIONS  
Chair: M.A. Piris, Santander (Spain)

17:15  023  FREQUENCIES OF LYMPHOMA ENTITIES AND IMPACT OF DIAGNOSTIC REVIEW: A FRENCH EXPERIENCE ON 35.753 LYMPHOMAS OVER 2010-2013  
C. Laurent, Toulouse (France)
RITUXIMAB TREATMENT IN FOLLICULAR LYMPHOMA CIRCUMVENTS THE PROGNOSTIC VALUE OF INTRA-TUMORAL T-CELLS: AUTOMATED IMAGE ANALYSIS OF THE LYSA PRIMA TRIAL
L. Xerri, Marseille (France)

CELL OF ORIGIN (COO) ASSIGNMENT IN TRANSFORMED FOLLICULAR LYMPHOMA
R. Kridel, Vancouver BC (Canada)

NOTCH1/2 MUTATIONS ARE RECURRENTLY FOUND IN CYCLIN D1-NEGATIVE SOX11-POSITIVE MANTLE CELL LYMPHOMA
I. Salaverria, Barcelona (Spain)

CLINICOPATHOLOGICAL STUDY OF HHV8-NEGATIVE BODY CAVITY-BASED LYMPHOMA (BCBL)
D. Kaji, Tokyo (Japan)

GREY ZONE LYMPHOMA BETWEEN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B CELL LYMPHOMA: A LYSA RETROSPECTIVE ANALYSIS
C. Sarkozy, Pierre Bénite (France)

TRANSPANTATION
Chair: S. Montoto, London (UK)

BEAM PLUS RITUXIMAB OR RADIOIMMUNOTHERAPY VERSUS BEAM FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED FOLLICULAR LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT
L. Bento, Paris (France)

OUTCOME OF REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER A PREVIOUS AUTOLOGOUS STEM CELL TRANSPLANT
S. Robinson, Bristol (UK)

A UK LYMPHOMA CLINICAL STUDY GROUP PHASE II EVALUATION OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN INTESTINAL AND OTHER AGGRESSIVE T-CELL LYMPHOMAS
M.M. Lannon, Newcastle upon Tyne (UK)

ALLOGENEIC TRANSPLANTATION FOR T-CELL LYMPHOMAS: NO DIFFERENCE IN OUTCOME BETWEEN PATIENTS ALLOGRAFTED UP-FRONT AND IN FIRST CHEMOSENSITIVE RELAPSE
A. Dodero, Milan (Italy)

ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION AS FIRST-LINE THERAPY FOR YOUNGER PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA - RESULTS OF THE INTERIM ANALYSIS OF THE AATT TRIAL
N. Schmitz, Hamburg (Germany)

POST TRANSPLANT CYCLOPHOSPHAMIDE REDUCES NON RELAPSE MORTALITY OF HAPLO-IDENTICAL TRANSPLANTS YIELDING SIMILAR OUTCOMES AS WITH MATCHED SIBLING DONORS
S. Dietrich, Heidelberg (Germany)

NOVEL AGENTS
Chair: G. Salles, Pierre Bénite (France)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15</td>
<td>035</td>
<td>LIPID ADDICTION OF DLBCL: INVOLVEMENT OF PI3K SIGNALING AND POTENTIAL THERAPEUTIC STRATEGIES VIA FATTY ACID SYNTAHE SMALL MOLECULE INHIBITORS</td>
<td>A. Evens</td>
<td>Boston, MA (USA)</td>
</tr>
<tr>
<td>17:25</td>
<td>036</td>
<td>EZH2 AND MYD88 MUTATIONS APPEAR ASSOCIATED WITH ANTITUMOR ACTIVITY OF THREE NEW BET BROMODomain INHIBITORS (BAY-5627, BAY-7575 AND BAY-8097) IN PRECLINICAL LYMPHOMA MODELS</td>
<td>E. Bernasconi</td>
<td>Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>17:35</td>
<td>037</td>
<td>VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): PHASE 1 RESULTS</td>
<td>J.L. Kaufman</td>
<td>Atlanta, GA (USA)</td>
</tr>
<tr>
<td>17:45</td>
<td>038</td>
<td>TGR-1202, A NOVEL ONCE DAILY PI3K Δ INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY IN PATIENTS WITH CLL AND B-CELL LYMPHOMA</td>
<td>H.A. Burris III</td>
<td>Nashville, TN (USA)</td>
</tr>
<tr>
<td>17:55</td>
<td>039</td>
<td>ONGOING, FIRST-IN-HUMAN, PHASE 1 DOSE-ESCALATION STUDY OF INVESTIGATIONAL SYK INHIBITOR TAK-659 IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA</td>
<td>A.M. Petrich</td>
<td>Chicago, IL (USA)</td>
</tr>
<tr>
<td>18:05</td>
<td>040</td>
<td>ARGX-110, A NOVEL MONOCLONAL ANTIBODY TARGETING CD70, IS ASSOCIATED WITH BIOLOGICAL ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMAS</td>
<td>M. Maerevoet</td>
<td>Villejuif (France)</td>
</tr>
</tbody>
</table>

Aula Magna, University Campus

**SHORT- AND LONG-TERM TOXICITY OF LYMPHOMA THERAPIES**
Chair: M.F. Fey, Bern (Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15</td>
<td>041</td>
<td>PULMONARY FUNCTION AND GRADE 3/4 CLINICAL EVENTS IN PET NEGATIVE PATIENTS TAKING PART IN THE INTERNATIONAL RATHL TRIAL (CRUK/07/033): A COMPARISON OF 12 VS 4 DOSES OF BLEOMYCIN</td>
<td>C. Hague</td>
<td>Manchester (UK)</td>
</tr>
<tr>
<td>17:25</td>
<td>042</td>
<td>SYK &amp; PI3K δ PATHWAY INHIBITION RESULTED IN INCREASED RATES OF PNEUMONITIS: IMPLICATIONS FOR DEVELOPING FUTURE SMALL MOLECULE COMBINATIONS</td>
<td>P.M. Barr</td>
<td>Rochester, NY (USA)</td>
</tr>
<tr>
<td>17:35</td>
<td>043</td>
<td>CARDIOVASCULAR DISEASE AFTER THERAPY FOR HODGKIN LYMPHOMA: A DETAILED ANALYSIS OF 9 COLLABORATIVE EORTC-LYSA TRIALS</td>
<td>M. Maraldo</td>
<td>Copenhagen (Denmark)</td>
</tr>
<tr>
<td>17:45</td>
<td>044</td>
<td>A RADIATION DOSE-RESPONSE RELATIONSHIP FOR RISK OF CORONARY HEART DISEASE IN SURVIVORS OF HODGKIN LYMPHOMA: A CASE-CONTROL STUDY</td>
<td>B.M. Aleman</td>
<td>Amsterdam (The Netherlands)</td>
</tr>
<tr>
<td>17:55</td>
<td>045</td>
<td>ANTICOAGULANT/ANTIPLATELET THERAPY CONCOMITANT WITH IDELALISIB IN CHRONIC LYMPHOCYTIC LEUKEMIA AND INDOLENT NHL: USE AND OUTCOMES</td>
<td>P. Ghia</td>
<td>Milan (Italy)</td>
</tr>
<tr>
<td>18:05</td>
<td>046</td>
<td>PATTERNS OF COGNITIVE DIFFiculties AFTER TREATMENT FOR LYMPHOMA</td>
<td>O.C. Lindner</td>
<td>Manchester (UK)</td>
</tr>
</tbody>
</table>
Thursday, June 18, 2015

08:30 – 18:30
Marquee

08:00 – 08:45
5 parallel sessions
Room A  XII. THERAPEUTIC EXPLOITATION OF AUTOLOGOUS T-CELL ACTIVATION IN B-CELL LYMPHOMA
A. Younes, New York, NY (USA)

Room B  XI. MANAGEMENT OF PEDIATRIC AND ADULT NON HODGKIN LYMPHOMA: WHAT LESSONS CAN EACH TEACH THE OTHER?
B. Burkhardt, Muenster (Germany) and J.F. Seymour, Melbourne (Australia)

Cinema Corso  III. CURRENT CONCEPTS IN PRIMARY CENTRAL NERVOUS LYMPHOMA
G. Illerhaus, Stuttgart (Germany)

Auditorium, University Campus  IV. MASSES IN THE MEDIASTINUM: PRIMARY MEDIASTINAL LYMPHOMA AND INTERMEDIATE TYPES
P.M.W. Johnson, Southampton (UK)

Aula Magna, University Campus  V. SMOLDERING MULTIPLE MYELOMA
M.V. Mateos, Salamanca (Spain)

09:00 – 10:35
Room A and (overflow area) Marquee

09:00  047  GERMINAL CENTERS AND LYMPHOMAGENESIS
R. Dalla-Favera, New York, NY (USA)

09:20  048  WHOLE EXOME SEQUENCING OF REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS IDENTIFIED RECURRENT MUTATIONS OF THE EXPOR1 N 1 GENE (XPO1) IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA SUBTYPE. A LYSA STUDY
F. Jardin, Rouen (France)

09:35  049  RECURRENT SOMATIC MUTATIONS IN DIFFUSE LARGE B CELL LYMPHOMA ASSESSED BY HIGH-THROUGHPUT TARGETED SEQUENCING HIGHLIGHT MOLECULAR SUBTYPES’ GENETIC DIVERGENCE: A LYSA STUDY
S. Dubois, Rouen (France)

09:50  050  A MODIFIED AUTOANTIGEN IS THE FIRST MOLECULARLY DEFINED RISK FACTOR AND A DOMINANT ANTIGENIC TARGET / STIMULUS OF THE B-CELL RECEPTOR FROM ABC-TYPE DLBCL
M. Pfreundschuh, Homburg (Germany)

10:05  051  THE ROLE OF TONIC BCR SIGNALING IN A MOUSE MODEL OF MYC-DRIVEN LYMPHOMA
S. Casola, Milan (Italy)

10:20  052  RECURRENT MTORC1-ACTIVATING RRAGC MUTATIONS ARE A FEATURE OF FOLLICULAR LYMPHOMA
J. Okosun, London (UK)
09:00 – 10:30
5 parallel sessions

“CASE DISCUSSION“ SESSIONS
Italian Lymphoma Foundation – FIL vs Cornell University and Memorial Sloan-Kettering Cancer Center in New York, NY (USA)

Room B
INDOLENT LYMPHOMAS
Chair: A. Davies, Southampton (UK)
Discussants: L. Arcaini, Pavia (Italy) and J.P. Leonard, New York, NY (USA)

Room C
PEDIATRIC AND ADOLESCENT LYMPHOMAS
Chair: W. Wössmann, Giessen (Germany)
Discussants: M. Pillon, Padua (Italy) and C. Bollard, Washington, DC (USA)

Cinema Corso
CLL
Chair: J.G. Gribben, London (UK)
Discussants: R. Foà, Rome (Italy) and A.D. Zelenetz, New York, NY (USA)

Auditorium, University Campus
T-CELL LYMPHOMAS
Chair: F. d’Amore, Aarhus (Denmark)
Discussants: P. Corradini, Milan (Italy) and S. Horwitz, New York, NY (USA)

Aula Magna, University Campus
HODGKIN LYMPHOMAS
Chair: J.A. Radford, Manchester (UK)
Discussants: P.L. Zinzani, Bologna (Italy) and A. Younes, New York, NY (USA)

10:35 – 11:00
COFFEE BREAK

11:00 – 12:00
SESSION 2 - ADVANCES IN CLL
Co-Chairs: M. Hallek, Cologne (Germany) and A.D. Zelenetz, New York, NY (USA)

11:00 053 IN-VIVO STUDIES OF KINETICS IN CHRONIC LYMPHOCYTIC LEUKAEMIA PROVIDE DEFINITIVE EVIDENCE OF LYMPH-NODE RE-ENTRY AND SUGGEST THAT THERE IS A NON-PROLIFERATIVE SUB-CLONE
K. Cuthill, London (UK)

11:15 054 THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI) – AN INTERNATIONAL META-ANALYSIS
J. Bahlo, Cologne (Germany)

11:30 055 EFFICACY OF IBRUTINIB VS OFATUMUMAB BY CYTOGENETIC AND CLINICAL SUBGROUPS IN A PHASE 3 TRIAL IN PATIENTS WITH PREVIOUSLY TREATED CLL/SLL
P. Thornton, Dublin (Ireland)

11:45 056 BFR (BENDAMUSTINE, FLUDARABINE, RITUXIMAB) ALLOGENEIC CONDITIONING IMPROVES SURVIVAL IN CLL
I.F. Khouri, Houston, TX (USA)

12:00 – 13:00
LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their posters for discussion with attendees
13:00 – 13:45
Room A, B and
Marquee
(overflow area)

**HENRY RAPPAPORT MEMORIAL LECTURE**
Chair: P. Gaulard, Créteil (France)

13:00 – 17:00
exact time TBC
Cinema Corso

**WORKSHOP FOR RADIATION ONCOLOGISTS**
Co-Chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)

- TECHNICAL CHALLENGES IN RADIATION THERAPY OF LYMPHOMAS
  B. Dabaja, Houston, TX (USA)
- Panel discussion: COMPETENCIES FOR RADIATION ONCOLOGISTS WITH SPECIAL EXPERTISE IN LYMPHOMAS

13:45 – 15:15
Room A, B and
Marquee
(overflow area)

**SESSION 3 – MANTLE CELL LYMPHOMA**
Co-Chairs: M. Dreyling, Munich (Germany) and P. Martin, New York, NY (USA)

13:45 057
PI3K INACTIVATION AND REDOX STRESS MEDIATES THERAPEUTIC TARGETING OF CDK4 IN MCL
S. Chen-Kiang, New York NY (USA)

14:00 058
PROGNOSTIC VALUE OF PROLIFERATION, CYTOLOGY, AND GROWTH PATTERN IN MANTLE CELL LYMPHOMA: RESULTS FROM RANDOMIZED TRIALS OF THE EUROPEAN MCL NETWORK
E. Hoster, Munich (Germany)

14:15 059
RITUXIMAB, BENDAMUSTINE AND CYTARABINE (RBAC500) AS INDUCTION THERAPY IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: A PHASE 2 STUDY FROM THE FONDAZIONE ITALIANA LINFOMI
C. Visco, Vicenza (Italy)

14:30 060
LENALIDOMIDE-RITUXIMAB-BENDAMUSTINE IN FIRST LINE FOR PATIENTS > 65 WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE NORDIC LYMPHOMA GROUP MCL4 (LENA-BERIT) PHASE I/II TRIAL
A. Albertsson-Lindblad, Lund (Sweden)

14:45 061
RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS ASCT IN UNTREATED PATIENTS WITH MCL: INTERIM ANALYSIS OF THE LYMA TRIAL, A LYSFA STUDY
S. Le Gouill, Nantes (France)

15:00 062
RESULTS OF A RANDOMIZED PHASE II TRIAL OF R-HCVAD VS. R-BENDAMUSTINE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTS FOR PATIENTS WITH MANTLE CELL LYMPHOMA: US INTERGROUP S1106
R. Chen, Duarte, CA (USA)

14:45 – 16:55
Room C

**SESSION 4 - PEDIATRIC LYMPHOMA**
Chair: W. Wössmann, Giessen (Germany)

14:45 063
NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS: THERAPEUTIC APPROACHES AND GREY ZONE TO MATURE B-NHL
C. Mauz-Koerholz, Halle (Germany)
NEW TARGETS FOR THE TREATMENT OF MATURE B-NHL
F. Jardin, Rouen (France)

RESULTS OF THE RANDOMIZED TRIAL EURO-LB02 ON LYMPHOBLASTIC LYMPHOMA IN CHILDREN AND ADOLESCENTS – A REPORT OF THE EUROPEAN INTERGROUP FOR CHILDHOOD NON-HODGKIN LYMPHOMA
B. Burkhardt, Muenster (Germany)

RELAPSES IN CHILDREN/ADOLESCENTS WITH MATURE B-CELL LYMPHOMA/LEUKEMIA TREATED IN THE RITUXIMAB ERA - A STUDY OF THE SOCIÉTÉ FRANÇAISE DES CANCERS DE L'ENFANT
V. Minard-Colin, Villejuif (France)

TREATMENT AND CHARACTERIZATION OF PATIENTS WITH BURKITT LYMPHOMA (BL): RESULTS FROM A SINGLE INSTITUTION IN NORTHERN UGANDA
V. Calbi, Gulu (Uganda)

RISK-ADAPTED APPROACH FOR PATIENTS WITH RELAPSED OR REFRACTORY ALCL – FINAL REPORT OF THE PROSPECTIVE ALCL-RELAPSE TRIAL OF THE EICNHL
S. Ruf, Giessen (Germany)

LYMPHOMA ASSOCIATED WITH A CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME: CLINICAL DESCRIPTION IN A FRENCH COHORT
N. Lavoine, Villejuif (France)

T-CELL PROJECT: AN INTERNATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS WITH AGGRESSIVE PERIPHERAL NK/T-CELL LYMPHOMA, LESSON FROM THE FIRST 1308 PATIENTS
M. Federico, Modena (Italy)

THE GENETIC LANDSCAPE OF HEPATOSPLENIC T-CELL LYMPHOMA REVEALS NOVEL STRATEGIES FOR TREATMENT AND RISK-STRATIFICATION
P. Gaulard, Créteil (France)

A PTCL, NOS SUBSET WITH MOLECULAR AND CLINICAL FEATURES SIMILAR TO AITL
M. Dobay, Lausanne (Switzerland)

RADIATION THERAPY FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (pcALCL): AN INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP (ILROG) MULTI-INSTITUTIONAL EXPERIENCE
R.T. Hoppe, Stanford, CA (USA)

TEN YEARS MEDIAN FOLLOW-UP OF THE NORDIC NLG-T-01 TRIAL ON CHOEP AND UPFRONT AUTOLOGOUS TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS
F. d’Amore, Aarhus (Denmark)
16:50 075 5-YEAR FOLLOW-UP OF THE SMILE PHASE II STUDY FOR NEWLY-DIAGNOSED STAGE IV, RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE
R. Suzuki, Izumo (Japan)

15:35 – 16:55 SESSION 6 – INTERFERING WITH BCR-NFKB PATHWAYS
Room B
Co-Chairs: M.A. Shipp, Boston, MA (USA) and F.E. Cotter, London (UK)

15:35 076 Introduction: BCR SIGNALING AND SURVIVAL PATHWAYS IN LYMPHOMA
M.A Shipp, Boston, MA (USA)

15:55 077 IBRUTINIB IS HIGHLY ACTIVE AND PRODUCES DURABLE RESPONSES IN PREVIOUSLY TREATED WALDENSTRÖM’S MACROGLOBULINEMIA
S. Treon, Boston, MA (USA)

16:10 078 THE NOVEL DUAL PI3K/MTOR INHIBITOR PQR309 SHOWS PRECLINICAL ACTIVITY AS SINGLE AGENT OR IN COMBINATION AND TARGETS CENTRAL SIGNALING PATHWAYS IN B-CELL LYMPHOMAS
C. Tarantelli, Bellinzona (Switzerland)

16:25 079 PHASE 1 STUDY OF PI3Kδ INHIBITOR INCB040093 ALONE OR IN COMBINATION WITH SELECTIVE JAK1 INHIBITOR INCB039110 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES
T.J. Phillips, Ann Arbor, MI (USA)

16:40 080 A FIRST-IN-HUMAN TRIAL OF CUDC-907, AN ORAL, FIRST-IN-CLASS, DUAL INHIBITOR OF PI3K AND HDAC, IN PATIENTS WITH REFRACTORY/RELAPSED LYMPHOMA AND MULTIPLE MYELOMA
A. Younes, New York, NY (USA)

17:15 – 18:15 “FOCUS ON…” SESSIONS

IMAGING
Chair: B.D. Cheson, Washington, D.C. (USA)

17:15 081 USE OF THE LUGANO CLASSIFICATION CRITERIA FOR PET/CT ASSESSMENT OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA AFTER IMMUNOCHEMOTHERAPY AND IRRADIATION IN THE IELSG-26 STUDY
L. Ceriani, Bellinzona (Switzerland)

17:25 082 PET SCORE FOLLOWING 3 CYCLES ABVD HAS GREATER PROGNOSTIC VALUE THAN PRE-TREATMENT RISK STRATIFICATION IN THE RAPID TRIAL IN EARLY STAGE HODGKIN LYMPHOMA (HL)
J.A. Radford, Manchester (UK)

17:35 083 BASELINE TOTAL METABOLIC VOLUME (TMTV0) PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) ENROLLED IN THE LNH07-3B LYSA TRIAL
O. Casasnovas, Créteil (France)

17:45 084 PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOUR VOLUME (TMTV0) MEASURED ON FDG-PET/CT IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA (PTCL)
A. Cottereau, Rouen (France)

17:55 085 LITTLE VALUE OF ROUTINE SURVEILLANCE IMAGING FOR PRIMARY CNS LYMPHOMAS IN FIRST REMISSION: RESULTS FROM A DANISH MULTICENTER STUDY
K. Juul Mylam, Odense (Denmark)
18:05  086  ROUTINE IMAGING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST REMISSION IS NOT ASSOCIATED WITH BETTER SURVIVAL: A DANISH-SWARDED POPULATION-BASED STUDY
T.C. El-Galaly, Aalborg (Denmark)

Room B

TARGETTING CD30
Chair: P. Borchmann, Cologne (Germany)

17:15  087  BRENTUXIMAB VEDOTIN PLUS AVD FOR NON-BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA: A PHASE 2 TRIAL
J.S. Abramson, Boston, MA (USA)

17:25  088  PRELIMINARY EFFICACY AND SAFETY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY INVOLVED-SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA
A. Kumar, New York, NY (USA)

17:35  089  SEQUENTIAL BRENTUXIMAB VEDOTIN AND AVD FOR OLDER HODGKIN LYMPHOMA PATIENTS: INITIAL RESULTS FROM A PHASE 2 MULTICENTER STUDY
A.M. Evens, Boston, MA (USA)

17:45  090  A PHASE 1 STUDY OF BRENTUXIMAB VEDOTIN (BV) AND BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) AND ANAPLASTIC LARGE T-CELL LYMPHOMA (ALCL)
J. Kuruvilla, Toronto, ON (Canada)

17:55  091  BRENTUXIMAB VEDOTIN DEMONSTRATES ANTITUMOR ACTIVITY IN CD30+ DLBCL
M.R. Smith, Boston, MA (USA)

18:05  092  UPDATED RESULTS OF A PHASE 2 TRIAL OF BRENTUXIMAB VEDOTIN COMBINED WITH RCHOP IN FRONTLINE TREATMENT OF PTS WITH HIGH-INTERMEDIATE/HIGH-RISK DLBCL
S.M. Ansell, Rochester, MN (USA)

Room C

EPIDEMIOLOGY AND INFECTIONS
Chair: L. Arcaini, Pavia (Italy)

17:15  093  INTERNATIONAL DLBCL STUDY FINDS BIOLOGICAL HETEROGENEITY BETWEEN ETHNICALLY DIVERSE COUNTRIES BUT SIMILAR IPI-ADJUSTED OUTCOMES
R. Carr, London (UK)

17:25  094  INVOLVEMENT OF MORAXELLA CATARRHALIS IN THE PATHOGENESIS OF HODGKIN LYMPHOMA (NODULAR LYMPHOCYTE PREDOMINANT TYPE, IGD-POSITIVE)
S. Hartmann, Frankfurt (Germany)

17:35  095  EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL
C. Visco, Vicenza (Italy)

17:45  096  EXPOSURE TO HEPATITIS B VIRUS (HBV), FAMILY HISTORY, AND B-CELL NON-HODGKIN LYMPHOMA (B-NHL): A CASE-CONTROL STUDY AMONG JEWS AND ARABS IN ISRAEL AND THE WEST BANK
O. Paltiel, Jerusalem (Israel)

17:55  097  EBV POSITIVE DLBCL OF THE ELDERLY IS A HETEROGENEOUS DISORDER WITH OUTCOME PREDICTED BY ITS IMMUNE MICROENVIRONMENT
C. Keane, Brisbane (Australia)
18:05 098 THE ROLE OF HBV-INFECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA
W. Xu, Nanjing (China)

Cinema Corso

MANAGEMENT OF T-CELL LYMPHOMA
Chair: F. d’Amore, Aarhus (Denmark)

17:15 099 CHOEP VS. CHOP GIVES BETTER RESULTS IN FIRST-LINE THERAPY OF T-CELL LYMPHOMA. A RETROSPECTIVE ANALYSIS FROM CZECH LYMPHOMA STUDY GROUP (CLSG) DATABASE
A. Janikova, Brno (Czech Republic)

17:25 100 LONG-TERM OUTCOME OF ADULTS WITH ALCL AFTER THE FIRST RELAPSE/PROGRESSION: A LYSA STUDY
D. Sibon, Paris (France)

17:35 101 PROSPECTIVE PHASE II TRIAL OF LENALIDOMIDE IN ASSOCIATION WITH CHOP IN ELDERLY PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL): INTERIM ANALYSIS OF A LYSA STUDY
V. Safar, Lyon (France)

17:45 102 CLINICAL OUTCOMES AND PROGNOSTIC FACTORS OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA
H. Yhim, Jeonju (Republic of Korea)

17:55 103 P-GEMOX REGIMEN FOLLOWED BY EXTENSIVE INVOLVED-FIELD RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II ENKTL
H. Hui-Qiang, Guangzhou (China)

18:05 104 HDAC INHIBITOR COMBINATIONS EXHIBIT SYNERGY IN PRE- AND CLINICAL EXPERIENCES IN DRUG RESISTANT T-CELL LYMPHOMA
O.A. O’Connor, New York, NY (USA)

Auditorium,
University Campus

NEW DRUG COMBINATIONS
Chair: J.P. Leonard, New York, NY (USA)

17:15 105 UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB ACHIEVES 95% ORR IN PATIENTS WITH HIGH-RISK RELAPSED/REFRACTORY CLL
J. Burke, Aurora, CO (USA)

17:25 106 THE CHEMOTHERAPY-FREE TRIPLET OF UBLITUXIMAB, TGR-1202, AND IBRUTINIB IS SAFE AND HIGHLY ACTIVE IN RELAPSED B-CELL MALIGNANCIES
L. Nastoupil, Houston, TX (USA)

17:35 107 A PHASE 1 STUDY OF PI3K & INHIBITOR INCB040093 ALONE OR IN COMBINATION WITH SELECTIVE JAK1 INHIBITOR INCB039110 IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA
A. Forero-Torres, Birmingham, AL (USA)

17:45 108 ABT-199 TRIGGERS APOPTOSIS, AND AUGMENTS IBRUTINIB CYTOTOXICITY IN CXCR4 WILD-TYPE AND WHITH MUTATED WALDENSTROEM MACROGLOBULINEMIA CELLS
J.J. Castillo, Boston, MA (USA)
VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1B RESULTS  
A.A. Chanan-Khan, Jacksonville, FL (USA)

CANCER ENERGY METABOLISM AS A THERAPEUTIC TARGET IN REFRACTORY MYC+ DIFFUSE LARGE B-CELL LYMPHOMA  
C. Thieblemont, Paris (France)

Aula Magna, University Campus

THE IELSG-37 STUDY: A RANDOMIZED TRIAL ASSESSING THE ROLE OF MEDIASTINAL RADIOTHERAPY AFTER FRONT-LINE RITUXIMAB AND ANTHRACYCLINE CONTAINING REGIMENS IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)  
M. Martelli, Rome (Italy)

ROCHOP STUDY: A PHASE III RANDOMIZED STUDY OF CHOP COMPARED TO ROMIDEPSIN-CHOP IN UNTREATED PERIPHERAL T-CELL LYMPHOMA  
R. Delarue, Paris (France)

CLL2-BIG, -BAG, -BCG AND -BIO: FOUR PHASE-II TRIALS EVALUATING A SEQUENTIAL TAILORED AND TARGETED REGIMEN AIMING FOR TOTAL ERADICATION OF MRD IN AN ALL-COMER CLL POPULATION  
P. Cramer, Cologne (Germany)

PHASE 2 STUDY OF VENETOCLAX (GDC-0199/ABT-199) PLUS BENDAMUSTINE AND RITUXIMAB (BR) VS. BR OR VENETOCLAX PLUS RITUXIMAB IN RELAPSED/REFRACTORY FL  
W. Hiddemann, Munich (Germany)

DLC-002 (ROBUST): PHASE III RANDOMIZED, EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS R-CHOP VS R-CHOP IN PATIENTS WITH UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA  
A. Chiappella, Turin (Italy)

RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF IBRUTINIB/OBINUTUZUMAB VS. CHLORAMBUCIL/OBINUTUZUMAB FOR TREATMENT-NAÏVE CLL/SLL (PCYC-1130; ILLUMINATE)  
C. Moreno, Barcelona (Spain)
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:35</td>
<td>Room A and Marquee (overflow area)</td>
<td><strong>SESSION 7 - LYMPHOMA BIOLOGY AND GENOMICS II</strong></td>
<td>Co-Chairs: T.M. Mak, Toronto, ON (Canada) and L. Pasqualucci, New York, NY (USA)</td>
</tr>
<tr>
<td>09:00</td>
<td>Room A and Marquee (overflow area)</td>
<td>111  <strong>ISOCITRATE DEHYDROGENASE (IDH) MUTATIONS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)</strong></td>
<td>T.M. Mak, Toronto, ON (Canada)</td>
</tr>
<tr>
<td>09:20</td>
<td>Room A and Marquee (overflow area)</td>
<td>112  <strong>RECURRENT MUTATIONS IN TCR (PATHWAY)-RELATED GENES IN TFH-DERIVED PERIPHERAL T-CELL LYMPHOMAS</strong></td>
<td>D. Vallois, Lausanne (Switzerland)</td>
</tr>
<tr>
<td>09:35</td>
<td>Room A and Marquee (overflow area)</td>
<td>113  <strong>HBZ, BCL-XL, AKT, AND LOSS OF INK4A/ARF SYNERGISTICALLY TRANSFORM PRIMARY MURINE T CELLS AND ELICIT ATL-LIKE DISEASE IN MICE</strong></td>
<td>Y. Kasugai, Nagoya (Japan)</td>
</tr>
<tr>
<td>09:50</td>
<td>Room A and Marquee (overflow area)</td>
<td>114  <strong>WHOLE GENOME SEQUENCING IN THE FRAMEWORK OF ICGC MMML-SEQ IDENTIFIES PCBP1 AS RECURRENTLY MUTATED IN BURKITT LYMPHOMA</strong></td>
<td>S.M. Aukema, Kiel (Germany)</td>
</tr>
<tr>
<td>10:05</td>
<td>Room A and Marquee (overflow area)</td>
<td>115  <strong>GENE, MIRNA AND PATHWAY SPECIFIC PROTEIN EXPRESSION ANALYSIS IN NEWLY DIAGNOSED MYC/BCL2 DOUBLE EXPRESSING DIFFUSE LARGE B-CELL LYMPHOMA</strong></td>
<td>E. Matsuki, New York, NY (USA)</td>
</tr>
<tr>
<td>10:20</td>
<td>Room A and Marquee (overflow area)</td>
<td>116  <strong>MECHANISMS OF MALIGNANT TRANSFORMATION IN TP53 WILD-TYPE BURKITT LYMPHOMA IDENTIFIED BY INTEGRATION OF MOLECULAR AND FUNCTIONAL GENOMICS DATA</strong></td>
<td>J. Huellein, Heidelberg (Germany)</td>
</tr>
</tbody>
</table>
09:00 – 10:30
5 parallel sessions
“CASE DISCUSSION” SESSIONS
Room B
AGGRESSIVE LYMPHOMAS
Chair: A. Lopez-Guillermo, Barcelona (Spain)
Discussants: U. Vitolo, Turin (Italy) and P. Hamlin, New York, NY (USA)

Room C
LYMPHOMA RADIOTHERAPY
Chair: L. Specht, Copenhagen (Denmark)
Discussants: U. Ricardi, Turin (Italy) and J. Yahalom, New York, NY (USA)

Cinema Corso
MULTIPLE MYELOMA
Chair: S.V. Rajkumar, Rochester, MN (USA)
Discussants: M. Cavo, Bologna (Italy) and M. Coleman, New York, NY (USA)

Auditorium, University Campus
MANTLE CELL LYMPHOMA
Chair: S. Le Gouill, Nantes (France)
Discussants: M. Martelli, Rome (Italy) and P. Martin, New York, NY (USA)

Aula Magna, University Campus
CLINICO-PATHOLOGICAL DISCUSSION: BORDER-LINE CASES*
Chair: M. Ghielmini, Bellinzona (Switzerland)
Presenters: S. Dirnhofer, Basel (Switzerland), E. Campo, Barcelona (Spain) and S.H. Swerdlow, Pittsburgh, PA (USA)
Discussants: M. Federico, Modena (Italy) and C.H. Moskowitz, New York, NY (USA)
*supported by an unrestricted grant by sigma-tau Research Switzerland SA

10:30 – 11:00
COFFEE BREAK, Marquee Parco Ciani

11:00 – 12:05
SESSION 8 – HODGKIN’S LYMPHOMA
Co-Chairs: R. Küppers, Essen (Germany) and J.A. Radford, Manchester (UK)

11:00 117
Introduction: BIOLOGY OF HODGKIN LYMPHOMA
R. Küppers, Essen (Germany)

11:20 118
INTERIM PET-ADAPTED CHEMOTHERAPY IN ADVANCED HODGKIN LYMPHOMA (HL). RESULTS OF THE SECOND INTERIM ANALYSIS OF THE ITALIAN GITIL/FIL DH0607 TRIAL
A. Gallamini, Nice (France)

11:35 119
INTERIM PET RESPONSE-ADAPTED THERAPY IN ADVANCED STAGE HODGKIN’S LYMPHOMA: FINAL RESULTS OF THE PHASE II PART OF THE FONDAZIONE ITALIANA LINFOMI (FIL) HD0801 STUDY
P.L. Zinzani, Bologna (Italy)

11:50 120
ANALYSIS OF PRIMARY-REFRACTORY HODGKIN LYMPHOMA PTS IN A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANT
C.H. Moskowitz, New York, NY (USA)

12:05 – 13:00
13-ICML PRESS CONFERENCE
(open to all journalists)

12:05 – 13:00
LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their posters for discussion with attendees
### JOHN ULTMANN MEMORIAL LECTURE* 🎤
Chair: E.S. Jaffe, Bethesda, MD (USA)
*sponsored by European School of Oncology - ESO

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>003</td>
<td>Thirty Years of Progress in Cutaneous Lymphoma Research</td>
<td>R. Willemze, Leiden (The Nederlands)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
</tbody>
</table>

### SESSION 9 – INDOLENT LYMPHOMA
Co-Chairs: B.S. Kahl, Madison, WI (USA) and A. Lopez-Guillermo, Barcelona (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:50</td>
<td>13-ICML Workshop Report</td>
<td>R. Gascoyne, Vancouver, BC (Canada)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
<tr>
<td>14:05</td>
<td>Risk of Transformation of Follicular Lymphoma and Outcome in the Immunochemotherapy Era: Ancillary Study from the Prima Trial</td>
<td>C. Sarkozy, Pierre Bénite (France)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
<tr>
<td>14:20</td>
<td>Complete Response Rate at 30 Months (CR30) as a Surrogate Endpoint in First-Line Follicular Lymphoma: A Prospectively Specified Analysis Using Individual Patient Data</td>
<td>D.J. Sargent, Rochester, MN (USA)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
<tr>
<td>14:50</td>
<td>A Simple and Effective Malt Lymphoma-Specific Prognostic Index Generated from the Dataset of the IELSG-19 Controlled Clinical Trial</td>
<td>C. Thieblemont, Paris (France)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
<tr>
<td>15:05</td>
<td>BING-NEEL Syndrome: A Multi-Institutional Retrospective Study</td>
<td>J.J. Castillo, Boston, MA (USA)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
</tbody>
</table>

### BREAK

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20</td>
<td></td>
<td></td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
</tbody>
</table>

### CONTROVERSY
Early-Stage HL: Should Interim PET-Based Therapy Be Considered Routine Clinical Practice?
Chair: T.A. Lister, London (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>006</td>
<td>No: M. Hutchings, Copenhagen (Denmark) vs</td>
<td></td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
<tr>
<td>007</td>
<td>Yes: J.M. Connors, Vancouver, BC (Canada)</td>
<td></td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
</tbody>
</table>

### SESSION 10 – AGGRESSIVE LYMPHOMA
Co-Chairs: U. Vitolo, Turin (Italy) and L.H. Sehn, Vancouver, BC (Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>Gray Zone Lymphoma (GZL): Characteristics, Outcomes and Prognostication Among a Large Multicenter Cohort</td>
<td>A.M. Evens, Boston, MA (USA)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
<tr>
<td>16:30</td>
<td>Ratios of T-Cells to Tumour Associated Macrophages and PD-1 Axis Molecules, Add to the Predictive Power of Conventional Prognosticators in Diffuse Large B Cell Lymphoma</td>
<td>M. Gandhi, Brisbane (Australia)</td>
<td>Room A, B and Marquee (overflow area)</td>
</tr>
</tbody>
</table>
CONTINUED RISK OF RELAPSE INDEPENDENT OF TREATMENT MODALITY IN LIMITED STAGE DIFFUSE LARGE B-CELL LYMPHOMA: FINAL AND LONG-TERM ANALYSIS OF SWOG STUDY S8736
D.M. Stephens, Salt Lake City, UT (USA)

TREATMENT SELECTION AND SURVIVAL OUTCOMES IN EARLY-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: DOES MODERN CHEMOTHERAPY REPLACE THE NEED FOR RADIOTHERAPY?
J.A. Vargo, Pittsburg, PA (USA)

FRONT LINE THERAPY WITH R-CODOX-M & R-IVAC IN POOR RISK DIFFUSE LARGE B CELL LYMPHOMA (IPI 3-5) YIELDS A GOOD OUTCOME WITHOUT TRANSPLANTATION: A PHASE 2 UK NCRI/LLR TRIAL
A.K. McMillan, Nottingham (UK)

VALIDATION OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL) PROGNOSTIC MODEL FOR CNS RELAPSE IN A LARGE COHORT OF PET/CT STAGED PATIENTS
T.C. El-Galaly, Aalborg (Denmark)

FAREWELL APERO

Marquee
Saturday, June 20, 2015

08:00 – 10:30
Room 159, University Campus

SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING*
A. Kil Berthelsen, Copenhagen (Denmark), S. Qi, New York, NY (USA) and Peking (China), L. Specht, Copenhagen (Denmark)
Organized by International Lymphoma Radiation Oncology Group - ILROG and European Society for Radiotherapy and Oncology – ESTRO
* compulsory pre-registration

08:30 – 10:00
2 parallel sessions
Room A

SESSION 11 – PRIMARY CNS LYMPHOMA
Co-Chairs: G. Illerhaus, Stuttgart (Germany) and A.J. Ferreri, Milan (Italy)

08:30 132
HIGH FREQUENCY OF MYD88 MUTATIONS IN VITREORETINAL B-CELL LYMPHOMA: A VALUABLE TOOL TO IMPROVE DIAGNOSTIC YIELD OF VITREOUS BODY ASPIRATES
I. Bonzheim, Tuebingen (Germany)

08:45 133
GENETIC BASIS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
K. Yoshida, Kyoto (Japan)

09:00 134
RITUXIMAB, METHOTREXATE, PROCARBAZINE AND LOMUSTINE FOR ELDERLY PRIMARY CNS LYMPHOMA PATIENTS – THE PRIMAIN-STUDY BY THE GERMAN COOPERATIVE PCNSL GROUP
B. Kasenda, Stuttgart (Germany)

09:15 135
MANAGEMENT AND OUTCOME OF PRIMARY CNS LYMPHOMA AT FIRST RELAPSE/PROGRESSION: ANALYSIS OF 256 PATIENTS FROM THE FRENCH LOC NETWORK
S. Langner-Lemercier, Rennes (France)

09:30 136
PHASE I/II STUDY OF TEDDI-R WITH IBRUTINIB IN UNTREATED AND RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA
K. Dunleavy, Bethesda, MD (USA)

09:45 137
LENALIDOMIDE IS HIGHLY ACTIVE IN RECURRENT CNS LYMPHOMAS: PHASE I INVESTIGATION OF LENALIDOMIDE PLUS RITUXIMAB AND OUTCOMES OF LENALIDOMIDE AS MAINTENANCE MONOTHERAPY
J.L. Rubenstein, San Francisco, CA (USA)

08:40 – 10:00
Room B

SESSION 12 – IMMUNOTHERAPY
Co-Chairs: R. Levy, Stanford, CA (USA) and F. Morschhauser, Lille (France)

08:40 138
Introduction: IMMUNOTHERAPY OF LYMPHOMA 2015
R. Levy, Stanford, CA (USA)

09:00 139
PHASE II TRIAL OF CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS DIRECTED AGAINST CD19 IN RELAPSED/REFRACTORY LARGE B CELL, FOLLICULAR, AND MANTLE CELL LYMPHOMAS
S.J. Schuster, Philadelphia, PA (USA)

09:15 140
A PHASE IIA STUDY OF SINGLE-AGENT MOR208, AN FC-OPTIMIZED ANTI-CD19 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
P.L. Zinzani, Bologna (Italy)
09:30 141 PHASE I, FIRST-IN-HUMAN TRIAL OF BI 836826 (AN ANTI-CD37 ANTIBODY) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
S. Stilgenbauer, Ulm (Germany)

09:45 142 TWO DOSES OF POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE
F. Morschhauser, Lille (France)

10:00 – 11:20 SESSION 13 – TARGETTING INTRACELLULAR PATHWAYS
Room A and B
Co-Chairs: M. Seto, Nagoya (Japan) and J.F. Seymour, Melbourne (Australia)

10:00 143 Introduction: GENETIC AND EPIGENETIC HETEROGENEITY OF MALIGNANT LYMPHOMA: CHALLENGING FEATURES
M. Seto, Nagoya (Japan)

10:20 144 EPIGENETIC CONTROL OF CELLULAR SENESCENCE IN TUMOR DEVELOPMENT AND LYMPHOMA TREATMENT
C.A. Schmitt, Berlin (Germany)

10:35 145 PHASE 1 STUDY OF E7438 (EPZ-6438), AN ENHANCER OF ZESTE-HOMOLOG 2 (EZH2) INHIBITOR: DOSE DETERMINATION AND PRELIMINARY ACTIVITY IN NON-HODGKIN LYMPHOMA
V. Ribrag, Villejuif (France)

10:50 146 SELINEXOR SHOWS ACTIVITY IN DOUBLE-HIT DIFFUSE LARGE B-CELL LYMPHOMA IN PRE-CLINICAL MODELS & IN PATIENTS WITH RELAPSED/REFRACTORY DOUBLE-HIT DLBCL
R. Garzon, Columbus, OH (USA)

11:05 147 PHASE 1 PRELIMINARY SAFETY, EFFICACY AND BIOMARKER DATA FROM VENETOCLAX (ABT-199/GDC-0199) + BENDAMUSTINE AND RITUXIMAB IN R/R NON-HODGKIN'S LYMPHOMA
S. de Vos, Los Angeles, CA (USA)

11:20 – 11:45 13-ICML HIGHLIGHTS
Room A and B
*TAKE HOME MESSAGES*
J.W. Friedberg, Rochester, NY (USA)

11:45 – 11:55 CLOSURE AND FAREWELL
F. Cavalli, Bellinzona (Switzerland)

13:30 – 18:00 WORKSHOP: “CANINE LYMPHOMAS: STATE OF THE ART AND COMPARATIVE ASPECTS WITH HUMAN DISEASE”*
Room B
Co-Chairs: S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy)
Organized by the European Canine Lymphoma Group
*open to all 13-ICML attendees

This icon denotes presentations that will be available online, only for 13-ICML attendees, between July 15 and September 15, 2015.